Empowering

people living with

rare immunologic diseases

We develop innovative immunomodulating therapies with the potential to transform the lives of people affected by rare immunologic conditions.

Media

Our latest announcements

Hansa Biopharma participating in Wedbush PacGrow Renal Summit

02/07/2026

Hansa Biopharma announces closing of €115 million licensing transaction with SERB Pharmaceuticals for Idefirix in Europe and MENA

Regulatory press release

01/07/2026

Hansa Biopharma announces ConfIdeS Phase 3 Abstract Selected for ‘What’s Hot, What’s New’ Plenary at ATC 2026

24/06/2026

Hansa Biopharma appoints Adam Cutler as new Chief Financial Officer

15/06/2026

Our science

Our unique antibody-cleaving enzyme technology

Our proprietary antibody-cleaving enzymes imilfidase and HNSA-5487 target and inactivate IgG antibodies in the blood and tissues, inhibiting the IgG-mediated immune responses, helping halt the progression of IgG-driven acute autoimmune diseases, as well as enable lifesaving and life altering procedures and therapies.

Science

Pipeline

Our focus area

We aim to address unmet need in conditions where the IgG-driven immune response becomes harmful, or it interferes with the delivery of lifesaving and life altering therapies.